Screener
Regenxbio RGNX Deferred Equity Offering Costs Reclassified
Deferred Equity Offering Costs Reclassified at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept rgnx:DeferredEquityOfferingCostsReclassified.
The source filing: Regenxbio’s 10-K, filed March 5, 2026. Open the filing →
- Filed
- Mar 5, 2026, 4:21 PM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-094013
FAQ
- What is Regenxbio's deferred equity offering costs reclassified?
- Regenxbio (RGNX) reported deferred equity offering costs reclassified of $124.75K in Q4 2025.
- How has Regenxbio's deferred equity offering costs reclassified changed year-over-year?
- Regenxbio's deferred equity offering costs reclassified decreased by 20.5% year-over-year, from $157K to $124.75K.
- What does deferred equity offering costs reclassified mean?
- Deferred Equity Offering Costs Reclassified as reported by REGENXBIO Inc..
Ask your AI about Regenxbio's deferred equity offering costs reclassified.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude